Hyderabad: Hyderabad-based Natco Pharma reported a dip in its net profit for the quarter ended September 30, 2021 to Rs 65.1 crore as against...
Hyderabad: A simple pill to treat Covid-19 positive patients! Yes, an anti-viral pill that could be easily prescribed and taken orally by Covid positive...
For the entire 2020-21 fiscal, the company posted a consolidated net profit of Rs 442 crore as compared with Rs 458 crore in 2019-20.
Natco Pharma had recently received approval from the Drug Controller General of India (DCGI) to conduct phase III clinical trials of Molnupiravir
Task Force also discussed with them various alternatives to drugs that are in high demand like Remdesivir
Stocks of Natco Pharma were trading 0.74 per cent lower at Rs 810.85 apiece on BSE.
Hyderabad-headquartered comprehensive cancer care provider expects to close Series A funding in the second half of 2021
With this launch, cotton farmers will have a new and powerful tool to manage PBW, Natco Pharma said.
The consolidated total income of the company stood at Rs 386 crore for the quarter under consideration.
During the year, Natco spent Rs 349 crore on capital expenditure, a majority of which was used to enhance capabilities of their manufacturing facilities
- Advertisement -